Payment overview · 2025
General Payments
$1,023.50
64 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher Stanley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA, KS · NPI 1144678368
Verified facts
What the public records show
CMS Open Payments records show Christopher Stanley, M.D. received $1,023.50 in general payments during 2025 across 64 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.56 | 16.9% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $149.54 | 14.6% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $145.64 | 14.2% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $129.05 | 12.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.88 | 10.6% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $92.19 | 9.0% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $91.05 | 8.9% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.08 | 2.9% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.34 | 2.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.83 | 2.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.30 | 2.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.67 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.37 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,023.50 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $149.54 | 10 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $120.71 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $115.91 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $113.51 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $92.19 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $91.05 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.17 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.69 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $46.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.19 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.08 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $29.34 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.34 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.30 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $13.14 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $12.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 275 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 237 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 230 | 50 |
| Omeprazole | Omeprazole | 215 | 56 |
| Gabapentin | Gabapentin | 179 | 39 |
| Simvastatin | Simvastatin | 179 | 45 |
| Lisinopril | Lisinopril | 178 | 57 |
| Losartan Potassium | Losartan Potassium | 158 | 45 |
| Potassium Chloride | Potassium Chloride | 128 | 32 |
| Metformin Hcl | Metformin Hcl | 118 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 101 | 28 |
| Prednisone | Prednisone | 101 | 70 |
| Sertraline Hcl | Sertraline Hcl | 91 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 25 |
| Carvedilol | Carvedilol | 83 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 13 |
| Alprazolam | Alprazolam | 74 | 17 |
| Finasteride | Finasteride | 74 | 19 |
| Metformin Hcl Er | Metformin Hcl | 74 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 74 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 72 | 18 |
| Alendronate Sodium | Alendronate Sodium | 67 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 26 |
| Warfarin Sodium | Warfarin Sodium | 63 | 13 |
| Jardiance | Empagliflozin | 62 | 14 |
| Famotidine | Famotidine | 59 | 16 |
| Allopurinol | Allopurinol | 58 | 19 |
| Ozempic | Semaglutide | 57 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 56 | 18 |
| Eliquis | Apixaban | 55 | 12 |
| Xarelto | Rivaroxaban | 55 | 11 |
| Donepezil Hcl | Donepezil Hcl | 54 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 14 |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 27 |
| Meloxicam | Meloxicam | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 15 |
| Benazepril Hcl | Benazepril Hcl | 47 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 37 |
| Lorazepam | Lorazepam | 44 | 14 |
| Mounjaro | Tirzepatide | 44 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 15 |
| Pregabalin | Pregabalin | 40 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Telmisartan | Telmisartan | 39 | 13 |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 38 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Furosemide | Furosemide | 38 | 16 |
| Atenolol | Atenolol | 37 | suppressed |
| Primidone | Primidone | 36 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 31 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 13 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 22 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 22 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Sotalol | Sotalol Hcl | 20 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Fluconazole | Fluconazole | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,023.50 · 64 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, KISUNLA, Kerendia, MOUNJARO, NURTEC ODT, NUZYRA, Ozempic, PROLIA, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, Wegovy, XHANCE, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error